The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease
Brakedal B, Dölle C, Riemer F, et al. Cell Metabolism 2022;34:396-407.e6.
What it found
Precursor study (NR). Well tolerated; brain NAD levels rose in some but not all patients, and those with a rise showed changes in brain metabolism and mild clinical improvement. Inflammatory markers in blood and spinal fluid fell.
Limitations
Phase 1 safety trial, small and short. Clinical findings were exploratory and need larger trials.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.